软组织肉瘤的靶向治疗进展  

A review on the advance of individualized therapy targeting soft tissue sarcomas

作　　者：任志午[1] 王国文[1] 

机构地区：[1]天津医科大学肿瘤医院骨与软组织肿瘤科,300060

出　　处：《中国骨与关节杂志》2015年第1期38-41,共4页Chinese Journal of Bone and Joint

摘　　要：软组织肉瘤（ soft tissue sarcoma，STS ）是源于间叶组织和与其交织生长外胚层神经组织的恶性肿瘤，包括除淋巴造血组织外的非上皮组织，即纤维、脂肪、肌肉、间皮以及分布于这些组织中的血管、淋巴管和外周神经，多位于四肢、躯干和腹膜后等部位，占成人恶性肿瘤的1%，儿童肿瘤的10%[1]。其主要特点为：分布广、类型多。根据世界卫生组织（ world health organization，WHO ）的分类，STS 具有60多种亚型，许多亚型易形成假包膜而被误认为良性[2]。其血行转移多见，易转移至肺。不表现为原位肿瘤，偶有软组织良性肿瘤转为恶性肿瘤，恶性外周神经鞘瘤除外。发病罕见、肿瘤异质性强、随机对照的临床研究少。Soft tissue sarcomas are malignant tumors derived from mesenchymal tissues and ectodermal neural tissues, with wide distribution and multi subtypes. Traditional treatment method of soft tissue sarcomas includes surgery, radiotherapy and chemotherapy. The treatment aims to control primary tumors and prevent the transfer of tumors. At present, molecular targeted drugs obtain positive effects in the treatment of common cancers such like non-small cell lung cancer, colorectal cancer, etc. Targeted therapeutic strategies suddenly become a new ifeld of cancer treatment. Antitumor drugs inhibit tumor growth by retarding tumor cell proliferation with the interference of tumor development and specific protein essential for the growth. Tumor-targeting drugs have fewer side effects and well tolerance. Currently, there are a variety of targeted drugs used in soft tissue sarcoma treatment. The individualized therapy provides different solutions according to the different tumor subtypes. It will be the future development trend of soft tissue sarcomas treatment.

关 键 词：分子靶向治疗 抗肿瘤药 软组织肿瘤 肉瘤 

分 类 号：R738.6[医药卫生—肿瘤]